The TH17 helper cells of the immune system have a dark side: they mediate autoimmune disorders. Two drugs that prevent the differentiation and activity of these cells might be of therapeutic value. See Letters p.486 & p.491
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Huh, J. R. et al. Nature 472, 486–490 (2011).
Solt, L. A. et al. Nature 472, 491–494 (2011).
Ivanov, I. I. et al. Cell 126, 1121–1133 (2006).
Jetten, A. M. Nucl. Recept. Signal. 7, e003 (2009).
Yang, X. O. et al. Immunity 28, 29–39 (2008).
Kumar, N. et al. Mol. Pharmacol. 77, 228–236 (2010).
O'Connor, W. Jr, Zenewicz, L. A. & Flavell, R. A. Nature Immunol. 11, 471–476 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jetten, A. A helping hand against autoimmunity. Nature 472, 421–422 (2011). https://doi.org/10.1038/472421a
Published:
Issue Date:
DOI: https://doi.org/10.1038/472421a
This article is cited by
-
Highlights of the advances in basic immunology in 2011
Cellular & Molecular Immunology (2012)
-
ROR blockers inhibit TH17 cells
Nature Reviews Neurology (2011)